- Conditions
- Rheumatoid Arthritis Interstitial Lung Disease
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 525 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 42 more
- Conditions
- Breast Cancer Related Lymphoedema, Lymphoedema
- Interventions
- LYT-100 BCRL, Placebo BCRL
- Drug
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Duarte, California • Los Angeles, California • Maitland, Florida + 1 more
- Conditions
- Interstitial Lung Disease
- Interventions
- Pirfenidone, Placebo controlled
- Drug · Other
- Lead sponsor
- Evans Fernandez Perez
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Scleroderma, Systemic, Interstitial Lung Disease
- Interventions
- Pirfenidone (PFD), Placebo (Plac), Mycophenolate Mofetil (MMF)
- Drug
- Lead sponsor
- Michael Roth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone, Placebo 2 capsules + Nintedanib or Pirfenidone, EGCG 600 mg + Nintedanib, EGCG 600 mg + Pirfenidone, Placebo 4 capsules + Nintedanib or Pirfenidone
- Combination Product
- Lead sponsor
- Hal Chapman
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- San Francisco, California • Boston, Massachusetts • Ann Arbor, Michigan + 4 more
- Conditions
- Covid19, Post-acute COVID-19 Respiratory Disease
- Interventions
- LYT-100, Placebo
- Drug · Other
- Lead sponsor
- PureTech
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Florence, Alabama • Los Angeles, California + 12 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 435 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Brisbane, California
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- VAY736, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Aurora, Colorado • Miami, Florida + 4 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTP001, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Kansas City, Kansas
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Valganciclovir, Placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- BI 1015550, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 11
- States / cities
- Clearwater, Florida • Gainesville, Florida • Kansas City, Kansas + 8 more
- Conditions
- Pancreatitis, Acute
- Interventions
- Pirfenidone Oral Tablet, Placebo
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Rochester, Minnesota
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
- Interventions
- AP01, Placebo
- Drug · Other
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 375 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 61
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Lebrikizumab, Pirfenidone, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 54
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 47 more
- Conditions
- Sarcoidosis, Pulmonary
- Interventions
- Pirfenidone, Placebos
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Albinism, Inborn Errors of Metabolism, Oculocutaneous Albinism, Platelet Storage Pool Deficiency, Pulmonary Fibrosis
- Interventions
- Pirfenidone, Placebo
- Drug
- Lead sponsor
- William Gahl, M.D.
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- GLPG1690, Placebo
- Drug
- Lead sponsor
- Lakefront Biotherapeutics NV
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 781 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 29 more
- Conditions
- Diabetes Mellitus, Diabetic Nephropathy
- Interventions
- Pirfenidone
- Drug
- Lead sponsor
- Sharma, Kumar, M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2009
- U.S. locations
- 3
- States / cities
- Bethesda, Maryland • Rochester, Minnesota • Philadelphia, Pennsylvania
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Pamrevlumab, Placebo, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Los Angeles, California • Sacramento, California + 23 more
- Conditions
- Long COVID
- Interventions
- Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
- Drug
- Lead sponsor
- Douglas D. Fraser
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 348 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Diego, California